Antidepressant effects of acute sleep deprivation are reduced in highly controlled environments.
Major depressive disorder
Mood
Sleep deprivation
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
18
04
2023
revised:
23
07
2023
accepted:
31
07
2023
pmc-release:
01
11
2024
medline:
11
9
2023
pubmed:
9
8
2023
entrez:
8
8
2023
Statut:
ppublish
Résumé
Numerous studies summarized in a recent meta-analysis have shown sleep deprivation rapidly improves depressive symptoms in approximately 50 % of individuals with major depressive disorder (MDD), however those studies were typically conducted in clinical settings. Here we investigated the effects of sleep deprivation utilizing a highly controlled experimental approach. 36 antidepressant-free individuals with MDD and 10 healthy controls (HC) completed a 5 day/4-night protocol consisting of adaptation, baseline, total sleep deprivation (TSD), and recovery phases. Light was kept consistently dim (≤50 lx), meals were regulated, and activity was restricted. In-the-moment mood was assessed using a modified Hamilton Rating Scale for Depression (HRSD) at screening and each morning following the experimental nights. Day of study had a significant effect on mood in both groups. Post-hoc analyses revealed that significant effects were attributed to mood improvement in the MDD group following study initiation prior to beginning TSD, and in the HC group following recovery sleep, but were not due to mood improvement in the MDD group during TSD. No further improvement in mood occurred during 36 h of TSD. Strict eligibility requirements may limit generalizability. The requirement to be medication free may have biased toward a less severely depressed sample. Results revealed that individuals with moderate MDD can experience a significant reduction in depressive symptoms upon entering a highly controlled laboratory environment. Environmental effects on mood can be substantial and need to be considered.
Sections du résumé
BACKGROUND
Numerous studies summarized in a recent meta-analysis have shown sleep deprivation rapidly improves depressive symptoms in approximately 50 % of individuals with major depressive disorder (MDD), however those studies were typically conducted in clinical settings. Here we investigated the effects of sleep deprivation utilizing a highly controlled experimental approach.
METHODS
36 antidepressant-free individuals with MDD and 10 healthy controls (HC) completed a 5 day/4-night protocol consisting of adaptation, baseline, total sleep deprivation (TSD), and recovery phases. Light was kept consistently dim (≤50 lx), meals were regulated, and activity was restricted. In-the-moment mood was assessed using a modified Hamilton Rating Scale for Depression (HRSD) at screening and each morning following the experimental nights.
RESULTS
Day of study had a significant effect on mood in both groups. Post-hoc analyses revealed that significant effects were attributed to mood improvement in the MDD group following study initiation prior to beginning TSD, and in the HC group following recovery sleep, but were not due to mood improvement in the MDD group during TSD. No further improvement in mood occurred during 36 h of TSD.
LIMITATIONS
Strict eligibility requirements may limit generalizability. The requirement to be medication free may have biased toward a less severely depressed sample.
CONCLUSIONS
Results revealed that individuals with moderate MDD can experience a significant reduction in depressive symptoms upon entering a highly controlled laboratory environment. Environmental effects on mood can be substantial and need to be considered.
Identifiants
pubmed: 37553017
pii: S0165-0327(23)00968-0
doi: 10.1016/j.jad.2023.07.116
pmc: PMC10528033
mid: NIHMS1925300
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
412-419Subventions
Organisme : CSRD VA
ID : IK2 CX001501
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH118580
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH107571
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Dr. Philip Gehrman has received research support from Merck, Inc. and has been a paid consultant for Eight Sleep, Eisai Inc., Fisher Wallace Laboratories, and Idorsia. All other authors declare no financial and personal relationships with other people or organizations that could inappropriately influence or bias this work.
Références
Dialogues Clin Neurosci. 2008;10(3):337-43
pubmed: 18979947
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1863-6
pubmed: 18801406
Clin Endocrinol (Oxf). 1999 Aug;51(2):205-15
pubmed: 10468992
J Psychiatr Res. 2001 May-Jun;35(3):155-63
pubmed: 11461711
Sleep Med Rev. 2002 Oct;6(5):361-77
pubmed: 12531127
Handb Exp Pharmacol. 2013;(217):311-31
pubmed: 23604485
Hum Psychopharmacol. 2008 Oct;23(7):571-85
pubmed: 18680211
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Psychol Med. 1988 Nov;18(4):1007-19
pubmed: 3078045
Depress Anxiety. 2001;14(1):37-49
pubmed: 11568981
J Clin Psychiatry. 2017 Sep/Oct;78(8):e986-e993
pubmed: 28922589
Expert Rev Neurother. 2010 Jul;10(7):1101-15
pubmed: 20586691
Biol Psychiatry. 2013 Jun 15;73(12):1164-71
pubmed: 22906517
Hum Neurobiol. 1982;1(3):205-10
pubmed: 7185793
Psychiatry Res. 1993 Mar;46(3):213-27
pubmed: 8493292
Hum Neurobiol. 1982;1(3):195-204
pubmed: 7185792
Neuropsychopharmacology. 2018 Dec;43(13):2572-2577
pubmed: 29872112
Psychol Med. 2019 Mar;49(4):639-645
pubmed: 29807554
Am J Psychiatry. 1999 Aug;156(8):1149-58
pubmed: 10450253
J Clin Psychiatry. 2017 Sep/Oct;78(8):e1020-e1034
pubmed: 28937707
Chronobiol Int. 2018 Sep;35(9):1319-1325
pubmed: 29764214
Am J Psychiatry. 1990 Jan;147(1):14-21
pubmed: 2403471
J Psychiatr Res. 1994 Jul-Aug;28(4):381-99
pubmed: 7877117
Am J Psychiatry. 2004 Dec;161(12):2163-77
pubmed: 15569884
Int J Chronobiol. 1976;4(2):97-110
pubmed: 1027738
Mol Psychiatry. 2013 Jun;18(6):692-9
pubmed: 23089630
Acta Neuropsychiatr. 2010 Feb;22(1):21-5
pubmed: 25384953
Biol Psychiatry. 1991 Apr 1;29(7):707-10
pubmed: 2054442